神经退行性疾病的植物医学:前进的道路
Dev Madhubala1,2, Aparup Patra2, Mojibur R Khan2
1Microbial Biotechnology and Protein Research Laboratory, Department of Molecular Biology and Biotechnology, Tezpur University, Tezpur, Assam, India.
Phytotherapy research : PTR
|April 11, 2024
概括
来自植物的化合物显示出治疗神经退行性疾病 (NDs) 的前景,如阿尔茨海默氏症和帕金森氏症. 本综述分析了植物药物,强调它们作为下一代ND治疗的潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
背景情况:
- 神经退行性疾病 (NDs) 是全球主要的死亡原因,其特点是神经元逐渐受损,影响记忆,认知和运动.
- 常见的ND包括帕金森氏症,阿尔茨海默氏症,亨廷顿氏症和肌缩侧面硬化症 (ALS).
- 目前的ND治疗面临的局限性包括耐药性,副作用和血脑屏障透能力差.
研究的目的:
- 批判性地分析关键植物药物治疗神经退行性疾病的特性和功效.
- 突出植物衍生化合物的优点和局限性,作为替代性ND处理方法.
- 审查奎尔塞丁,黄素,EGCG,阿皮基宁和大麻素的潜力.
主要方法:
- 对所选植物药物的临床前和临床研究的文献综述.
- 对植物化合物的疗效和安全性科学数据的分析.
- 评估这些化合物在克服当前治疗局限性的潜力.
主要成果:
- 来自植物的天然化合物在神经退行性疾病中显示出显著的治疗前景.
- 特定的化合物,如奎尔塞丁,黄素,EGCG,阿皮基宁和大麻素显示出潜在的益处.
- 植物药物可能比传统治疗提供优势,包括改善生物可用性和穿透血脑屏障.
结论:
- 植物药物是开发神经退行性疾病新型治疗方法的有希望的途径.
- 进一步进行广泛的临床前和临床研究是必不可少的,以将这些发现转化为有效的治疗方法.
- 植物性药物有可能成为下一代治疗方法,解决当前治疗策略的局限性.
相关概念视频
Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
122
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
122
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K


